NEW YORK--(BUSINESS WIRE)--
Philip Morris International Inc.’s (NYSE / Euronext Paris: PM) Chief Financial Officer, Jacek Olczak, will address investors today at the Barclays Global Consumer Staples Conference in Boston.
The presentation and Q&A session are being webcast live, in a listen-only mode, beginning at approximately 1:30 p.m. ET, at www.pmi.com/webcasts. Highlights of the presentation include updates on the company’s July year-to-date performance in key geographies, as well as the commercialization and clinical assessment of its reduced-risk product, iQOS.
“Our third quarter is off to a positive start, and this augurs well for the balance of the year. Robust fundamentals have driven favorable cigarette volume and share performance,” said Jacek Olczak, Chief Financial Officer. “iQOS is performing at or above our expectations and we are very encouraged by the results of our clinical studies thus far.”
Philip Morris International Inc.
Philip Morris International Inc. (PMI) is the leading international tobacco company, with six of the world's top 15 international brands, including Marlboro, the number one cigarette brand worldwide. PMI's products are sold in more than 180 markets. In 2014, the company held an estimated 15.6% share of the total international cigarette market outside of the U.S., or 28.6% excluding the People's Republic of China and the U.S. For more information, see www.pmi.com.
Reduced-Risk Products ("RRPs") is the term the company uses to refer to products with the potential to reduce individual risk and population harm in comparison to smoking combustible tobacco products such as cigarettes. One of our strategic priorities is to develop, assess and commercialize a portfolio of innovative RRPs. Our RRPs are in various stages of development and commercialization, and we are conducting extensive and rigorous scientific studies to determine whether they reduce exposure to harmful and potentially harmful constituents and ultimately reduce disease risk, compared to cigarettes. Any claims we make are based on a full set of data from the relevant scientific studies and may also be subject to government review and approval, as is the case in the U.S. today.
|New York: +1 (917) 663 2233|
|Lausanne: +41 (0)58 242 4666|
|Lausanne: +41 (0)58 242 4500|